BioAge Labs Reports Q1 2026 Financial Results with Key Metrics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy BIOA?
Source: seekingalpha
- Financial Performance: BioAge Labs reported a Q1 2026 GAAP EPS of -$0.52, which, while a loss, aligns with expectations, indicating the company's ongoing investment in R&D during its developmental phase.
- Revenue Growth: The company achieved revenue of $2.8 million in Q1, exceeding market expectations, suggesting a gradual increase in market demand within the biopharmaceutical sector.
- Cash Position: As of March 31, 2026, BioAge Labs held approximately $384.9 million in cash and cash equivalents, which is projected to fund operations and capital expenditures through 2029, enhancing investor confidence in its financial stability.
- R&D Progress: BioAge Labs is advancing the development of the BGE-102 NLRP3 inhibitor, with expectations to establish proof of concept in cardiovascular applications this year, indicating potential breakthroughs in the field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIOA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIOA
Wall Street analysts forecast BIOA stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 17.990
Low
15.00
Averages
37.00
High
73.00
Current: 17.990
Low
15.00
Averages
37.00
High
73.00
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioAge Labs Reports Q1 2026 Financial Results with Key Metrics
- Financial Performance: BioAge Labs reported a Q1 2026 GAAP EPS of -$0.52, which, while a loss, aligns with expectations, indicating the company's ongoing investment in R&D during its developmental phase.
- Revenue Growth: The company achieved revenue of $2.8 million in Q1, exceeding market expectations, suggesting a gradual increase in market demand within the biopharmaceutical sector.
- Cash Position: As of March 31, 2026, BioAge Labs held approximately $384.9 million in cash and cash equivalents, which is projected to fund operations and capital expenditures through 2029, enhancing investor confidence in its financial stability.
- R&D Progress: BioAge Labs is advancing the development of the BGE-102 NLRP3 inhibitor, with expectations to establish proof of concept in cardiovascular applications this year, indicating potential breakthroughs in the field.
See More
BioAge Labs Reports Positive Phase 1 Data for BGE-102
- Clinical Trial Progress: BioAge Labs reported positive Phase 1 data for BGE-102 in April 2026, demonstrating median hsCRP reductions of 86% across 60mg and 120mg dose groups, indicating potential best-in-class efficacy in managing cardiovascular risk, which could reshape treatment strategies.
- Follow-up Trial Plans: The company plans to initiate a Phase 2 dose-ranging trial and a Phase 1b/2a trial for BGE-102 in mid-2026, targeting cardiovascular risk and diabetic macular edema respectively, with data expected by the end of 2026 and mid-2027, further validating its clinical value.
- Successful Financing: BioAge completed an upsized follow-on public offering raising approximately $132.3 million in 2026, which will fund the clinical development of BGE-102 and other projects, ensuring sufficient capital ahead of key milestones and enhancing market competitiveness.
- Financial Performance: In Q1 2026, BioAge reported collaboration revenue of $2.8 million, a 93% increase year-over-year, while R&D expenses reached $20.4 million, primarily driven by the BGE-102 program, reflecting the company's ongoing investment in R&D and confidence in future growth.
See More
Leqembi Iqlik PDUFA Date Extended to August 24
- FDA Review Extension: The U.S. FDA has extended the review period for the supplemental Biologics License Application for Leqembi Iqlik by three months, with a new PDUFA date of August 24, 2026, indicating a thorough review process that may impact the drug's market entry timeline.
- Clinical Data Support: Eisai believes that the comprehensive clinical data package evaluating Leqembi strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which could significantly enhance its competitive position upon approval.
- Global Regulatory Confidence: Leqembi has been approved in 53 countries, reflecting broad regulatory confidence in its efficacy as a treatment option for early Alzheimer's disease, which may facilitate future market expansion opportunities.
- Strategic Partnership: BioArctic has maintained a long-term collaboration with Eisai since 2005 for the development of Leqembi, with BioArctic holding commercialization rights in the Nordic region, suggesting a strategic approach to maximize market reach through partnership.
See More
BioAge Labs Announces R&D Day Webcast Featuring BGE-102 Data
- Clinical Data Release: BioAge Labs will host a webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, targeting atherosclerotic cardiovascular disease (ASCVD) and retinal disease, which is expected to enhance investor confidence in the company's R&D progress.
- Expert Participation: The event will feature four leading academic and clinical experts, including Dr. Michael Davidson from the University of Chicago, who will discuss NLRP3 biology and its implications in ASCVD and retinal diseases, thereby increasing public understanding of BGE-102's potential.
- Therapeutic Mechanism Discussion: BioAge's management will elaborate on BGE-102's unique mechanism as an oral NLRP3 inhibitor, emphasizing its application in reducing cardiovascular risk and retinal diseases, potentially offering new treatment options for patients.
- Future Data Expectations: Phase 2 cardiovascular risk proof-of-concept data for BGE-102 are anticipated in H2 2026, with Phase 1b/2a diabetic macular edema proof-of-concept data expected in mid-2027, further validating its clinical value and advancing subsequent R&D efforts.
See More
BioAge Labs' BGE-102 Shows Promising Phase 1 Results
- Clinical Trial Success: BioAge Labs' oral NLRP3 inhibitor BGE-102 demonstrated significant reductions in hsCRP, a key inflammation marker, in a Phase 1 study involving obese participants, with 85% and 86% reductions at Day 7 and Day 21 respectively, indicating strong anti-inflammatory potential.
- Safety Profile: BGE-102 was well tolerated across all dose levels, with no serious adverse events or discontinuations reported, establishing a solid foundation for its clinical application and future trials.
- Future Trial Plans: BioAge intends to advance BGE-102 into a Phase 2 dose-ranging proof-of-concept trial in participants at elevated cardiovascular risk in the first half of 2026, with a Phase 3 trial expected to initiate in 2027, further validating its clinical value.
- Market Performance: BIOA's stock has traded between $3.67 and $24.00 over the past year, closing at $18.80 on Monday and rising 10.64% to $20.80 in pre-market trading, reflecting positive market sentiment regarding the drug's prospects.
See More
BioArctic Publishes 2025 Annual and Sustainability Reports
- Performance Breakthrough: BioArctic achieved record profits in 2025, marking a new phase of growth for the company after over 20 years of development, highlighting significant advancements in Alzheimer's disease treatment.
- Innovative Drug Launch: The company launched Leqembi, the world's first drug proven to slow the progression of Alzheimer's disease, further solidifying its leadership in neurodegenerative disease treatment and expected to drive future revenue growth.
- Sustainability Strategy: BioArctic's Sustainability Report is integrated with the Annual Report to enhance transparency and meet stakeholder expectations, inspired by the European Corporate Sustainability Reporting Directive, demonstrating the company's commitment to sustainable business practices.
- R&D Investment: The company is not only focused on Leqembi but also developing antibodies against Parkinson's disease and ALS, utilizing its proprietary BrainTransporter™ technology to enhance treatment efficacy, showcasing its broad research potential in the biopharmaceutical sector.
See More
BioAge Labs Reports Q1 2026 Financial Results with Key Metrics
- Financial Performance: BioAge Labs reported a Q1 2026 GAAP EPS of -$0.52, which, while a loss, aligns with expectations, indicating the company's ongoing investment in R&D during its developmental phase.
- Revenue Growth: The company achieved revenue of $2.8 million in Q1, exceeding market expectations, suggesting a gradual increase in market demand within the biopharmaceutical sector.
- Cash Position: As of March 31, 2026, BioAge Labs held approximately $384.9 million in cash and cash equivalents, which is projected to fund operations and capital expenditures through 2029, enhancing investor confidence in its financial stability.
- R&D Progress: BioAge Labs is advancing the development of the BGE-102 NLRP3 inhibitor, with expectations to establish proof of concept in cardiovascular applications this year, indicating potential breakthroughs in the field.
See More
BioAge Labs Reports Positive Phase 1 Data for BGE-102
- Clinical Trial Progress: BioAge Labs reported positive Phase 1 data for BGE-102 in April 2026, demonstrating median hsCRP reductions of 86% across 60mg and 120mg dose groups, indicating potential best-in-class efficacy in managing cardiovascular risk, which could reshape treatment strategies.
- Follow-up Trial Plans: The company plans to initiate a Phase 2 dose-ranging trial and a Phase 1b/2a trial for BGE-102 in mid-2026, targeting cardiovascular risk and diabetic macular edema respectively, with data expected by the end of 2026 and mid-2027, further validating its clinical value.
- Successful Financing: BioAge completed an upsized follow-on public offering raising approximately $132.3 million in 2026, which will fund the clinical development of BGE-102 and other projects, ensuring sufficient capital ahead of key milestones and enhancing market competitiveness.
- Financial Performance: In Q1 2026, BioAge reported collaboration revenue of $2.8 million, a 93% increase year-over-year, while R&D expenses reached $20.4 million, primarily driven by the BGE-102 program, reflecting the company's ongoing investment in R&D and confidence in future growth.
See More
Leqembi Iqlik PDUFA Date Extended to August 24
- FDA Review Extension: The U.S. FDA has extended the review period for the supplemental Biologics License Application for Leqembi Iqlik by three months, with a new PDUFA date of August 24, 2026, indicating a thorough review process that may impact the drug's market entry timeline.
- Clinical Data Support: Eisai believes that the comprehensive clinical data package evaluating Leqembi strongly supports its potential use as an initiation therapy for early Alzheimer's disease, which could significantly enhance its competitive position upon approval.
- Global Regulatory Confidence: Leqembi has been approved in 53 countries, reflecting broad regulatory confidence in its efficacy as a treatment option for early Alzheimer's disease, which may facilitate future market expansion opportunities.
- Strategic Partnership: BioArctic has maintained a long-term collaboration with Eisai since 2005 for the development of Leqembi, with BioArctic holding commercialization rights in the Nordic region, suggesting a strategic approach to maximize market reach through partnership.
See More
BioAge Labs Announces R&D Day Webcast Featuring BGE-102 Data
- Clinical Data Release: BioAge Labs will host a webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, targeting atherosclerotic cardiovascular disease (ASCVD) and retinal disease, which is expected to enhance investor confidence in the company's R&D progress.
- Expert Participation: The event will feature four leading academic and clinical experts, including Dr. Michael Davidson from the University of Chicago, who will discuss NLRP3 biology and its implications in ASCVD and retinal diseases, thereby increasing public understanding of BGE-102's potential.
- Therapeutic Mechanism Discussion: BioAge's management will elaborate on BGE-102's unique mechanism as an oral NLRP3 inhibitor, emphasizing its application in reducing cardiovascular risk and retinal diseases, potentially offering new treatment options for patients.
- Future Data Expectations: Phase 2 cardiovascular risk proof-of-concept data for BGE-102 are anticipated in H2 2026, with Phase 1b/2a diabetic macular edema proof-of-concept data expected in mid-2027, further validating its clinical value and advancing subsequent R&D efforts.
See More
BioAge Labs' BGE-102 Shows Promising Phase 1 Results
- Clinical Trial Success: BioAge Labs' oral NLRP3 inhibitor BGE-102 demonstrated significant reductions in hsCRP, a key inflammation marker, in a Phase 1 study involving obese participants, with 85% and 86% reductions at Day 7 and Day 21 respectively, indicating strong anti-inflammatory potential.
- Safety Profile: BGE-102 was well tolerated across all dose levels, with no serious adverse events or discontinuations reported, establishing a solid foundation for its clinical application and future trials.
- Future Trial Plans: BioAge intends to advance BGE-102 into a Phase 2 dose-ranging proof-of-concept trial in participants at elevated cardiovascular risk in the first half of 2026, with a Phase 3 trial expected to initiate in 2027, further validating its clinical value.
- Market Performance: BIOA's stock has traded between $3.67 and $24.00 over the past year, closing at $18.80 on Monday and rising 10.64% to $20.80 in pre-market trading, reflecting positive market sentiment regarding the drug's prospects.
See More
BioArctic Publishes 2025 Annual and Sustainability Reports
- Performance Breakthrough: BioArctic achieved record profits in 2025, marking a new phase of growth for the company after over 20 years of development, highlighting significant advancements in Alzheimer's disease treatment.
- Innovative Drug Launch: The company launched Leqembi, the world's first drug proven to slow the progression of Alzheimer's disease, further solidifying its leadership in neurodegenerative disease treatment and expected to drive future revenue growth.
- Sustainability Strategy: BioArctic's Sustainability Report is integrated with the Annual Report to enhance transparency and meet stakeholder expectations, inspired by the European Corporate Sustainability Reporting Directive, demonstrating the company's commitment to sustainable business practices.
- R&D Investment: The company is not only focused on Leqembi but also developing antibodies against Parkinson's disease and ALS, utilizing its proprietary BrainTransporter™ technology to enhance treatment efficacy, showcasing its broad research potential in the biopharmaceutical sector.
See More
